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Abstract 
 
Methicillin-Resistant Staphylococcus aureus (MRSA) has developed resistance towards a 
number of antibiotics. This resistance creates a challenge when trying to treat MRSA 
with a number of antibiotics. This is mainly caused by the penicillin-binding proteins 2a 
(PBP2a). PBP2a have significantly less affinity for beta-lactam antibiotics compared to 
the other penicillin-binding proteins (PBPs) expressed by non-resistant strains. New 
treatments involving a combination of antibiotics and herbal extracts are being developed 
and used to inactivate PBP2a, allowing the previous ineffective antibiotics to be more 
effective. 
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Current Antibiotics and Future Herbal Extract Methods to Treat Methicillin-Resistant 
Staphylococcus aureus (MRSA): Focusing on Inhibition of Penicillin-Binding Protein 2a 
(PBP2a) 
Staphylococcus aureus is a Gram-positive bacterium discovered in the 1880s. S. 
aureus is a pathogenic bacterium that causes infections as minor as those that affect the 
skin to severe post-operative wound complications. During the early 1940s, before the 
use of penicillin to treat S. aureus infections, these infections had a mortality rate as high 
as 80%, but as soon as penicillin started being used as a treatment option in 1942, a first 
resistant strain was isolated in a hospital. In 1962, a similar situation happened, where 
after the introduction of penicillin derivatives as an alternative to penicillin for treatment 
for S. aureus infections, resistant strains were isolated (Public Health in the 21st Century: 
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
These resistant strains were observed in the hospitals as well as in the community, which 
led to the coining of the terms Hospital Acquired-MRSA (HA-MRSA) and Community 
Acquired-MRSA (CA-MRSA). 
Currently, S. aureus is one of the major pathogens in the world. S. aureus is a 
serious threat to the public health and is a major nosocomial infection since hospitals are 
concentrated with people with weakened immunity (Wishart, Loughrey, McClurg, 
Goldsmith, & et al., 2007; Kelley, Jousselin, Barras, Lelong, & Renzoni, 2015; Otero et 
al., 2013). The high usage of implanted prosthetic biomaterials contribute to some of the 
cases involving MRSA outbreaks in hospitals since such devices could be breeding 
grounds for MRSA colonies (Pozzi et al., 2012). Compared to other clinically important 
bacteria, MRSA distinguishes itself from the rest because the bacterium possesses a 
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variety of virulence factors including the production of biofilms; MRSA is resistance to a 
broad spectrum of antimicrobial drugs and can be found in both hospital and community 
settings at significantly high occurrences (Public Health in the 21st Century: MRSA 
(Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
Penicillin-Binding Protein (PBP) 
 
The bacterial cell wall is an important part of the overall structure of the cell. The 
cell wall is mainly composed of peptidoglycan that help the bacterium to resist 
intracellular and extracellular pressures while maintaining the rigidity of the cell 
(Sauvage, Kerff, Terrak, Ayala, & Charlier, 2008). This also helps give the bacterial cell 
a more defined shape compared to animal cells that lack a cell wall. Likewise, penicillin- 
binding proteins (PBP) are responsible for the polymerization and cross-linkage of 
peptidoglycans to form the bacterium cell wall (Sauvage et al., 2008). The last D-alanine 
of stem pentapeptides is one of the main regions on the peptidoglycans used by PBPs 
during cross-linkage. These cross-linking regions have structural similarities to penicillin 
(and its derivatives) that allow some PBPs form acyl-enzymes with the penicillin, 
inhibiting any cross-linking capabilities (Sauvage et al., 2008). 
There are many different types of PBPs coded by different genes. Bacteria can 
have as many as 6 different PBPs. PBPs are divided into two main groups: the high 
molecular mass (HMM) PBPs, and the low molecular mass (LMM) PBPs (Sauvage et al., 
2008). HMM PBPs deal with polymerization of peptidoglycans and insertion of 
peptidoglycans into the cell walls of pre-existing cells. LMM PBPs mainly deal with cell 
remodeling activities such as cell separation, peptidoglycan maturation, and recycling 
(Sauvage et al., 2008). 
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Penicillin-Binding Protein 2a (PBP2a) 
 
Penicillin-binding protein 2a (PBP2a) is an alternative structural protein 
synthesized by MRSA to take over the functions of normal PBPs when subjected to stress 
in the environment, such as through the addition of antibiotics. PBP2a has an extremely 
lower affinity for antibiotics than the normal PBPs, which creates a serious problem when 
developing new antibiotics against MRSA (Pinho, de Lencastre, & Tomasz, 2001; Pinho, 
Filipe, de Lencastre, & Tomasz, 2001). PBP2a consists of an N-terminal transmembrane 
anchor, a C-terminal transpeptidase domain, and a bilobal nonpenicillin-binding domain 
(Figure 1). The protein is approximately 130 by 60 by 58 Å, where Å= 10-10 m (D. Lim & 
 
Natalie, 2002). The mecA gene is responsible for encoding PBP2a (Alexander, 2003; 
Ender, Berger-Bachi, & McCallum, 2009; Haghighat, Siadat, Sorkhabadi, Sepahi, & 
Mahdavi, 2013; Kim et al., 2013; D. Lim & Natalie, 2002). The acquired mecA gene is 
only 2.1 kilobases (kb) in length and is located on the S. aureus chromosome in the 
mobile genetic element that is known as staphylococcal cassette chromosome mec 
(SCCmec) (Pozzi et al., 2012). Although this element is mobile and capable of being 
transferred from one bacterium to another, SCCmec still inserts itself at specific and 
consistent positions on the S. aureus chromosome. (Katayama, Robinson, Enright, & 
Chambers, 2005; Public Health in the 21st Century: MRSA (Methicillin Resistant 
Staphylococcus aureus) Infections and Treatment, 2010). 
There are currently seven identified variants of the SCCmec that differ in their 
size but serve the same function of conferring antibiotics resistance to MRSA (Katayama 
et al., 2005). SCCmec type 1 contains 34.3 kb; type IV contains 20.9-24.3kb; type V 
contains 28 kb; type VI has 20.9 kb; and type VII has 35.9 kb. These variants confer 
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Figure 1: Structure of PBP2a. Reprinted by permission from Macmillan Publishers Ltd: 
[NATURE STRUCTURAL & MOLECULAR BIOLOGY] (D. Lim & Natalie, 2002), 
copyright (2002). 
 
resistance against β-lactam antibiotics only. The type II (53.0 kb) and III (66.9 kb) confer 
resistance against multiple classes of antibiotics (Public Health in the 21st Century: 
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
However, the mecA gene is not always active. The mecA gene is only active when 
normal PBPs fail to function or are inhibited by antibiotics. The SCCmec also contains 
other genes, mecR1 and mecI that serve as regulatory components to the mecA gene 
(Ender et al., 2009; McKinney, Sharma, Craig, & Archer, 2001). These regulatory genes 
have promoter regions that overlap with that of mecA. The mecR1 encodes a protein that 
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senses the stress in the bacterial environment and activates the mecA gene. The mecI 
gene does the opposite and is responsible for repressing the transcription of mecA when 
the bacterium does not need PBP2a (Ender et al., 2009; McKinney et al., 2001). 
Therefore, in order for PBP2a to be synthesized, mecR1 needs to be activated; otherwise, 
mecI will suppress the gene. Some bacteria lack both mecR1 and mecI. This DNA 
segment is either truncated or absent all together. In these bacteria, the regulation of 
mecA is controlled by the blaR1/blaI genes. These genes work in a similar fashion to 
mecR1/mecI. The blaR1/blaI genes regulate the transcription of blaZ, which codes for β- 
lactamases, enzymes that degrade β-lactam antibiotics such as penicillin (Ender et al., 
2009; McKinney et al., 2001). This is way that bacteria like MRSA confer resistance 
against antibiotics. In the absence of both mecR1/mecI and blaR1/blaI, the mecA will be 
always turned on, and so the majority of the cell wall proteins synthesized will be PBP2a, 
and not the normal PBP. 
When the bacterium senses the surrounding environment contains toxic levels of 
antibiotics, its transmembrane sensors, mecR1/blaR1, undergo a conformational change, 
which is followed by autoproteolytic cleavage of the n-terminal of the cytoplasmic 
domain of the transmembrane sensors. This activates the cytoplasmic peptidases, which 
degrade the repressor proteins of the blaZ/mecA genes, and begins the transcription of 
their respective proteins (Ender et al., 2009). 
The minimum inhibitory concentrations (MIC) of antibiotics are MRSA-strain 
specific. The MICs of antibiotics of two strains of MRSA can be close to one another or 
have a large difference. MICs for an antibiotic like oxacillin can start as low as 1 µg/ml to 
as high as values greater than 500 µg/ml (Ender et al., 2009). At this point the MICs are 
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not clinically practical and the strain is therefore considered resistant to antibiotics. 
Experiments have also shown that there are other genomic factors, collectively known as 
fem/aux factors, that work together with the mecA gene that confers antibiotic resistance 
to MRSA. These include genes that are involved in the synthesis of the precursors needed 
in the formation bacterial cell wall such as teichoic acid synthesis (Ender et al., 2009). 
The cell wall of MRSA and other Gram-positive bacteria is made up of 
peptidoglycan macromolecules that are cross-linked to each other. These molecules 
provide the necessary strength and stability, which helps in maintaining the shape of the 
bacteria, and protect the bacteria from osmotic influences of the environment (Public 
Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus) 
Infections and Treatment, 2010). Peptidoglycans are the building blocks of bacterial cell 
walls and are made up of alternating chains of N-acetylglucosamine and N- 
acetylmuramic acid residues connected by peptide bridges (Public Health in the 21st 
Century: MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 
2010). 
The synthesis of peptidoglycans involves three stages. The first stage takes place 
in the cytoplasm and involves taking a UDP-linked N-acetylmuramic acid molecule and 
sequentially adding amino acids. During the second stage, the sugar residue is transferred 
to bactoprenol, a lipid carrier. The lipid carrier transports the sugar residue across the 
cytoplasmic membrane. At this point N-acetylglucosamine residues will be added. In the 
third stage, which takes place on the outer surface of the plasma membrane, 
transglycosyation occurs, where polysaccharide chains are added to the existing chain 
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(Public Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus) 
Infections and Treatment, 2010). 
Treatments 
 
Common Treatments 
 
Bacterial infections are mainly treated by antibiotics. Bacterial species can differ 
in terms of their overall structure and metabolic process, which creates a need to develop 
different kinds of antibiotics to counter specific strains of bacteria. There are at least 11 
different classes of antibiotics, each with its own sub-classes and unique members (Table 
1). These classes include aminoglycosides, β-lactams, glycopeptides, lipopeptide, 
macrolide, oxazolidinone, quinolone, and tetracycline (Bush, 2012). Each class has a 
specific mechanism of action. The β-lactams, glycopeptide, lipopeptide, and colistin 
(polymixin E) target the cell membranes of the bacteria. Aminoglycosides, macrolides, 
ketolides, tetracycline, oxazolidinone, and streptogramins block protein synthesis. 
Quinolone and sulfa drugs mainly affect DNA and replication (Hauser, 2013). But the list 
from table 1 is not all inconclusive. There are currently many other antibiotics available 
for clinical use, and many others that are in the clinical trial phase. 
Vancomycin. Vancomycin is one of the most important antibiotics used to treat 
Gram-positive infections like MRSA. Vancomycin is a tricyclic glycopeptide with a large 
and a complex structure that works mainly by inhibiting the formation of the bacterial 
cell wall (Figure 2; McNamara & Steckelberg, 2005). Vancomycin halts the production 
of peptidoglycans, which form the basis of the cell wall of bacteria and binds to the D- 
alanyl- D-alanine terminal of the cell wall subunits (McNamara & Steckelberg, 2005). 
Other drugs such as penicillins and cephalosporins can also inhibit the production of 
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Table 1: Classes and sub-classes of different antibiotics 
 
Reprinted from Current Opinion in Pharmacology, Vol 12, Karen Bush, Improving 
known classes of antibiotics: an optimistic approach for the future, 527-534, Copyright 
(2012), with permission from Elsevier. 
 
 
 
Figure 2: The structure of Vancomycin. From the National Library of Medicine, accessed 
November 30, 2016, at 
http://www.nlm.nih.gov/pubs/techbull/ma00/ma00_chemid_fig8.html 
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bacterial cell wall. These drugs usually disrupt the process of cell wall formation wall in 
similar stages and sometimes result in cross-resistance of antibiotics, where the resistance 
against one type of drug can allow an organism to be resistant to a different type of drug. 
Vancomycin is not usually faced with problems of cross-resistance since many of the 
other antibiotics affect the cell wall formation process at a much different stage. 
Vancomycin can be used to treat the majority of Gram-positive bacteria; however, 
vancomycin is almost useless against Gram-negative bacteria. The cell wall composition 
of Gram-negative bacteria is slightly different from that of Gram-positive bacteria like 
Staphylococci species (McNamara & Steckelberg, 2005). The cell walls of Gram- 
negative bacteria are thinner and have slightly different amino acid linkers than Gram- 
positive bacteria. 
Vancomycin doses are usually administered intravenously to treat systemic or 
orthopedic infections. This is because the absorption of vancomycin in the 
gastrointestinal tract is low, and most of the drug will pass through unchanged. Oral 
doses are mainly used for infections that are in the gastrointestinal tract such as colitis 
caused by Gram-positive bacteria such as Clostridium difficile. Once in the blood stream, 
vancomycin is mainly excreted through renal glomerular filtration. The liver metabolizes 
only a small fraction of the drug (McNamara & Steckelberg, 2005). 
Although drug-resistance continues to be a problem with many antibiotics, 
vancomycin is still considered the first-line of attack against invasive MRSA infections. 
Vancomycin was developed over 50 years ago, and is still one of the strongest drugs used 
against these infections (Public Health in the 21st Century: MRSA (Methicillin Resistant 
Staphylococcus aureus) Infections and Treatment, 2010). Over the years vancomycin has 
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been used for various conditions including endocarditis, pneumonia, and wound 
infections. The cure rates for these conditions are 63%, 75%, and 90%, respectively 
(Public Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus) 
Infections and Treatment, 2010). But vancomycin still faces challenges in some aspects 
such as the treatment of lung infections because of the poor penetration rate. Also, some 
strains of bacteria including MRSA have been reported to develop resistance against 
vancomycin. 
Vancomycin faces additional criticism from some of its adverse reactions that 
some patients develop from its use. There have been reports for nephrotoxicity when 
treatments are combined with aminoglycoside agents. Another adverse reaction seen in 
patients taking vancomycin is “Red man syndrome”, which is caused by rapid infusion of 
vancomycin leading to a reddish itchy rash on the upper trunk, neck and face as a result 
of histamine release (McNamara & Steckelberg, 2005). 
Quinupristin and dalfopristin. Quinupristin and dalfopristin are antibiotics that 
are members of the class streptogramins. These antibiotics, which are administered 
intravenously, became available for use in the United States in 1999 (Hauser, 2013). 
Individually, the drugs have moderate antibacterial activity but are much more effective 
when used together. These antibiotics inhibit protein synthesis in bacteria by binding to 
the large (50S) subunit of the bacterial ribosome. Dalfopristin causes a conformational 
change in the ribosome, which allows the binding of quinupristin (Hauser, 2013). Even 
though quinupristin and dalfopristin have shown great potency against MRSA, there have 
also been numerous cases of resistance against these antibiotics. Resistance against 
quinupristin and dalfopristin have been due to conformational modification of the 
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ribosome, which prevents the binding of streptogramins; as a result, there have been 
reported cross-resistance with drugs such as macrolides and clindamycin because of 
having similar binding regions (Hauser, 2013). Enzymatic degradation of the drugs and 
efflux pumps are other factors that could lead to drug resistance (Hauser, 2013). 
Daptomycin. Another option that can be used to treat MRSA infections is 
daptomycin. Daptomycin is a cyclic lipopeptide consisting of 13 amino acids with a 
decanoyl side chain that has been used to treat complicated skin and soft tissue infections 
(cSSTIs) (Figure 3) (Public Health in the 21st Century: MRSA (Methicillin Resistant 
Staphylococcus aureus) Infections and Treatment, 2010). Daptomycin is derived from 
Streptomyces roseosporus as a fermentation product. Studies have shown that 
daptomycin is as effective as vancomycin in treating MRSA related bacteremia and 
endocarditis. Daptomycin is also as effective against Methicillin-Sensitive 
Staphylococcus aureus (MSSA). Its high potency and rapid bactericidal activity, 
especially against S. aureus, suggests daptomycin can be a better alternative in patients at 
risk of serious complications of infection such as those on dialysis who are suffering from 
blood stream infections caused by strains of S. aureus (Public Health in the 21st Century: 
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
There is a low risk associated with the development of spontaneous mutational resistance 
against daptomycin. This compounded with its ability to not develop cross-resistance 
with other known classes of antibiotics provides an excellent alternative to treating S. 
aureus related infections, including both resistant and non-resistant groups since there 
have been cases where patients develop severe complications as a result of vancomycin 
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Figure 3: Daptomycin Structure. Reprinted from Chemistry & Biology, Vol 11, Jason 
Micklefield, Daptomycin Structure and Mechanism of Action Revealed, 887-888, 
Copyright (2004), with permission from Elsevier. 
 
doses when the bacteria is MSSA and not MRSA (Public Health in the 21st Century: 
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
Linezolid. A synthetic oxazolidone that binds to the bacterial 23S ribosomal RNA 
of the 50S ribosomal subunit, linezolid, inhibits protein synthesis (Figure 4). Linezolid 
has shown success against S. aureus infections as well as other Gram-positive bacteria. 
The efficacy of linezolid has been shown to be similar to vancomycin. Compared to 
vancomycin, there have been fewer reports of resistance, which may be due to its lower 
usage. Failed treatments when using linezolid are usually caused by deep infections and 
failures to drain abscesses (Public Health in the 21st Century: MRSA (Methicillin 
Resistant Staphylococcus aureus) Infections and Treatment, 2010). 
Proposed Alternative Treatment Methods 
 
Duabanga grandiflora on MRSA biofilms. Many factors allow bacterial cells to 
become resistant to antibiotics. One such factor is the ability of the bacterial cells to grow 
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Figure 4: Structure of linezolid. Reprinted from Tuberculosis, Vol 88, Linezolid, 122- 
125, Copyright (2008), with permission from Elsevier. 
 
in biofilms. Biofilms significantly increase the resistance of bacteria to antibiotics by 
protecting bacteria from any changes in their immediate environment including the 
introduction of any potential antimicrobial agents. Studies have shown that biofilms 
created by immobile organisms, such as MRSA, are physiologically different from those 
of mobile organisms like planktons, which also allow for a greater survival rate within 
the infected hosts. Also, these two groups of organisms have different modes of growth 
(Santiago, Kuan-Hon, Hwei-San, & Kang Nee, 2015). This difference contributes to their 
resistance towards antibiotics. Therefore, treatments for infections involving biofilm- 
producing bacteria like MRSA are much more difficult to create, which could lead to 
chronic device-related infections (infections associated with surgically implanted medical 
devices) (Santiago et al., 2015). 
MRSA’s ability to form biofilms is one of the features that have allowed this 
microbe’s increased occurrence as a nosocomial infection whose treatments are made 
difficult by other virulence factors such as the PBP2a protein. Studies have shown that 
PBP2a is involved in the formation of biofilms in MRSA (Santiago et al., 2015). One 
hypothesis suggests that PBP2a facilitates interactions between cells in the development 
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of biofilms (Santiago et al., 2015). Therefore, plausible approaches in developing new 
treatments against MRSA infections is through the development of drugs that disrupt any 
of the steps involved in biofilm production, or interfere with the expression of PBP2a 
proteins which would eventually affect biofilm production. 
Duabanga is a genus in the plant kingdom originally placed in the Sonneratiaceae 
family. Presently, Duabanga is classified under the subfamily Duabangoideae of the 
family Lythraceae. Duabanga is indigenous to Southeast Asia (Malik et al., 2016). 
Duabanga consists of three main species, Duabanga grandiflora, Duabanga moluccana, 
and Duabanga taylorii Jayaweera. In some parts of Southeast Asia including Malaysia, 
the three species have other names used to identify them, Berembang Bukit, Megawasih, 
and Pedada Bukit, respectively (Malik et al., 2016). 
D. grandiflora trees, the subject of this section, which grow up to 30m high, are 
commonly found along valleys and streams in tropical evergreen forests. These trees, and 
especially its leaves, have been shown to possess medicinal properties. The leaves help 
stimulate the production of type II collagen, which helps heal inflammation and slow the 
aging process of the skin. The leaf extracts are also used to treat skin conditions including 
eczema and atopic dermatitis (Malik et al., 2016; Santiago et al., 2015). Patients with 
such skin conditions are generally predisposed to Staphylococcus aureus infections. 
Extracts and purified fractions obtained from D. grandiflora have been shown to inhibit 
bacterial growth. In addition to growth inhibition, studies have shown that these extracts 
and fractions re-sensitized MRSA towards ampicillin and other antibiotics that were 
previously ineffective against MRSA (Santiago et al., 2015). These extracts contain high 
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concentration of phytochemicals such as tannins, phenolic compounds, flavonoids and 
steroids. These phytochemicals also possess antiviral properties against human and 
animal viruses. 
In one study, Santiago et al. used a semi-purified fraction isolated from D. 
grandiflora by sequential extraction using hexane, ethyl acetate, and ethanol. This 
fraction named F-10 significantly inhibited the production of biofilms in bacterial 
cultures including MRSA; hence, the results were an indication of promising anti-MRSA 
activity (Santiago et al., 2015). As expected, F-10 contained tannins, flavonoids, and 
steroids, among other things. Flavonoids disrupt the activity of sortase, a bacterial 
enzyme known to influence the adhesive property of bacterial cell walls (Santiago et al., 
2015). This suggests that the presence of flavonoids in F-10 may explain its ability to 
inhibit the production of biofilms by MRSA. This study also revealed that MRSA 
cultures had a significantly lower expression of PBP2a in their biofilms when treated 
with F-10 (Santiago et al., 2015). Disruption of biofilms and lower expression of PBP2a 
due to D. grandiflora extract treatments may make MRSA less virulent and more 
susceptible to antibiotics such as ampicillin that were previously ineffective. 
Acalypha wilkesiana on PBP2a. A genus in the plant kingdom that is comprised 
of about 450 different species of plants (S. W. Lim et al., 2011), Acalypha wilkesiana is a 
shrub belonging to the Euphorbiaceae family, sometimes referred to as the spurge family 
(S. W. Lim et al., 2011; Odoh et al., 2014; Olukunle, Adenubi, Biobaku, & Sogebi, 
2015). This species is mainly found in Fiji and nearby islands in the South Pacific. Over 
the years, its occurrence has spread to other parts of the world, especially the tropics of 
Africa, America, and Asia. As a result, this species of plants has gathered a wide variety 
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of names that people commonly use to refer to the plant. Some of these common names 
are Joseph’s coat, referring to the different colors observed on its leaves, red leaf, fire 
dragon, beefsteak plant and match-me-if-you-can. In Northern Nigeria, the Hausa people 
named the plant “Jiwene” and “Jinwinini,” while the Yoruba people of Southern Nigeria 
named the tree “aworoso” (S. W. Lim et al., 2011; Odoh et al., 2014; Olukunle et al., 
2015). In western parts of Nigeria, the aqueous leaf extract of A. wilkesiana has been 
used as a short-term remedy for neonatal jaundice, whereas in the south, the extract is 
mostly used for the treatment of skin infections in children (Odoh et al., 2014). A. 
wilkesiana has been reported to show antimicrobial properties against a variety of 
bacteria, including Staphylococcus aureus, Yersinia enterocolitica, Escherichia coli, 
Salmonella typhi, Pseudomonas aeruginosa, and Klebsiella aerogenes. The effects of A. 
wilkesiana on S. aureus led to further studies on antibiotic resistant strains of bacteria 
such as MRSA. Extracts from the plant have also been used in the management of 
hypertension, diabetes, gastrointestinal disorders, pain management and has potential 
cytotoxic effects against cancerous cells. 
PBP2a is one of the key factors that confer antibiotics resistance to MRSA. 
Therefore, inactivating or decreasing the production of PBP2a will significantly help in 
the fight against MRSA. Santiago et al. observed that purified extracts of A. wilkesiana 
when used in conjunction with ampicillin, a non-effective treatment against MRSA, had 
synergistic properties, which resulted in increased susceptibility of MRSA to ampicillin. 
The minimum inhibitory concentration (MIC) of ampicillin needed to elicit antibacterial 
activity against MRSA is not practical and cannot be used in a hospital setting since 
ampicillin at such concentration would be toxic to patients, and therefore have no clinical 
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application. However, when extracts from A. wilkesiana are used in combination with 
ampicillin, the MIC of ampicillin drops significantly lower. This value is also lower than 
the MIC of ampicillin needed to inhibit the growth of sensitive strains of Staphylococcus 
aureus (Santiago et al., 2014). Using western blot analysis of the MRSA strains showed 
low expression levels the PBP2a protein in those cultures treated with the purified 
extracts from A. wilkesiana. Although extracts from the plant decreased the expression of 
PBP2a proteins in MRSA, such extracts did not show any bactericidal properties 
(Santiago et al., 2014), meaning, these extracts can make MRSA less resistant, but not 
kill the bacteria. This creates the possibility of combining ampicillin and the extracts to 
overcome ampicillin resistance, but at a much lower concentration than would normally 
be needed. 
The study conducted by Santiago et al. demonstrated the antimicrobial activity of 
the extract of A. wilkesiana. Furthermore, the extract showed a synergistic relationship 
between the extract, which was named 9EA-FC-B, and ampicillin in the inhibition of 
PBP2a production, which also allowed the MRSA cultures to be inhibited by ampicillin. 
The growth of MRSA was distinctly suppressed when both, the extract and ampicillin, 
were used compared to MRSA cultures that were treated alone with either compound. 
This effect was mainly observed during the exponential phase of the bacteria kinetic 
growth curve (Santiago et al., 2014). The exponential phase is the greatest increase in 
growth of bacteria observed in the presence of necessary nutrients. There was minimal 
MRSA growth during this stage when 9EA-FC-B and ampicillin were introduced in their 
environment. Changes were also observed during the lag phase of MRSA growth. This is 
the stage where the bacteria begin to acclimate or adapt to changes in the environment. 
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This stage was observed to take longer in MRSA cultures treated with 9EA-FC-B and 
ampicillin (Santiago et al., 2014). Previous studies have shown compounds such as 
corilagin and tellimagrandin I posses similar antimicrobial activities (Santiago et al., 
2014). Corilagin and tellimagrandin I are weak carbonic anhydrase inhibitors and are 
present in numerous plants including Punica granatum, Myrtaceae, and Elaegnaceae. 
Corilagin has also been previously isolated from A. wilkesiana, which suggests that the 
active ingredient in the 9EA-FC-B extract maybe corilagin (Santiago et al., 2014). 
Pongamia pinnata effect on MRSA. Pongamia pinnata is a legume that belongs 
in the subfamily Papilionoideae (Scott et al., 2008; Yadav et al., 2011). P. pinnata is 
commonly found in the Indian subcontinent and South-east Asia. Presently, P. pinnata 
can be found in other parts of the world such as Australia, New Zealand, China, USA, 
Philippines, and the humid tropical regions of the world. The tree derives its name from 
the Tamil language of India (Scott et al., 2008). Other names associated with P. pinnata 
are “Ponga,” “Dalkaramacha,” “Pongam,” “Punku,” “Karanj,” “Papar,” and “Kanji.” P. 
pinnata is a medium-sized evergreen tree that grows easily on alluvial and coastal 
environment in areas found at sea level to 1200m above sea level, and one of the most 
admired city trees in India due to its glowing lime-green colors (Scott et al., 2008). 
P. pinnata contains various phytochemical compounds. The most common ones 
are flavonoids and fixed oils. The seeds of P. pinnata also contain two sterols, three sterol 
derivatives, and one disaccharide, as well as eight fatty acids, of which three were 
saturated. The leaves and stem of the tree are the major sites for flavonoids and chalcone 
derivatives (Scott et al., 2008). 
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A number of herbal remedies involve parts of the plant, P. pinnata. There have 
been several documented reports that show that root extracts of the plant had significant 
prophylactic abilities against aspirin-induced ulceration, although little success was 
observed against ethanol-induced ulcerations. The root extracts helped to augment the 
mucosal cells, mucosal cell glycoproteins, cell proliferation, and prevent lipid 
peroxidation in the stomach walls (Scott et al., 2008). 
P. pinnata has also shown promise in antibacterial activities. One notable impact 
is its effect against MRSA. A study by Inala et al. showed crude extracts from P. pinnata 
seeds were tested on clinically significant pathogens such as Klebsiella pneumonia, 
Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Micrococcus luteus, 
and non-resistant strains of Staphylococcus aureus. Positive results from this study 
prompted more tests to be done on MRSA (Inala et al., 2015). A phytochemical analysis 
of the plant seeds showed the presence of alkaloids, tannins, saponins, steroids, 
glycosides and flavonoids (Inala et al., 2015). Inala et al. isolated the flavonoid 
components using adsorption column chromatography and used an agar well diffusion 
assay to test the efficacy of the extracted flavonoids against MRSA strains that were still 
susceptible to vancomycin, and the results were compared to MRSA strains that were 
resistant to vancomycin (Inala et al., 2015). The results were similar, in which the 
compounds displayed similar antibacterial capabilities against both vancomycin-resistant 
and vancomycin-sensitive MRSA strains. Therefore, extracts from P. pinnata have 
promising potential substitutes for antibiotics against MRSA that are no longer effective. 
Curcuma longa against MRSA. A perennial tree that belongs to the 
Zingiberaceae family (Reddy et al., 2012), Curcuma longa usually grows up to a height 
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of 1m and can be found distributed in the tropical and subtropical regions of the world 
but mainly cultivated in India and China. In India, commonly known as “Haldi,” 
Malaysia, and Indonesia, there have been numerous studies on the plant due to the 
economic importance in Malaysia and Indonesia. Other vernacular names associated with 
C. longa are “Haridra” from the Telugu language, “Manjal” from the Malayalam and 
Tamil language, and “Arisina” from the Kannada language (Reddy et al., 2012). All these 
language groups are indigenous to India. C. longa is considered a sterile plant because of 
its inability to produce any seeds. C. longa is used for both medicinal and food 
preparation. The rhizomes of the plant are commonly used as household remedies in 
Nepal (Reddy et al., 2012). There have been several claims in India that the plant can be 
used to fight against biliary disorders, anorexia, coryza (an inflammation of the mucous 
membrane of the nose, often caused by colds or hay fever), cough, diabetic wounds, 
hepatic disorders, rheumatism and sinusitis. The plant can also be boiled, dried and 
grounded to make turmeric, a bright yellow spice (Reddy et al., 2012). 
Curcumin or diferuloymethane is a phenolic diketone (Sharma, Gescher, & 
Steward, 2005). Curcumin has a molecular weight of 368.37 and melts at 183 degrees 
Celsius. There are three isoforms of curcumin that have been identified in C. longa: 
Curcumin I, Curcumin II, and Curcumin III (Figure 5). In acidic and neutral 
environments as well as in cell membranes, the bis-keto form of curcumin predominates 
(Figure 6). The enolate predominates in basic environments where curcumin acts as an 
electron donor (Sharma et al., 2005). 
Curcumin has a low rate of absorption. Pharmacokinetic studies in animals have 
shown that about 40 to 85% of curcumin administered orally passed through the 
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Figure 5: Isoforms of curcumin (Reddy et al., 2012). 
 
 
Figure 6: Tautomerism of curcumin. The top one predominates in acidic/neutral 
conditions, whereas the bottom one predominates in basic conditions. Reprinted from 
European Journal of Cancer, Vol 41, R.A. Sharma, A.J. Gescher, W.P. Steward, 
Curcumin: The story so far, 1955-1968, Copyright (2005), with permission from 
Elsevier. 
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gastrointestinal tract and remained unchanged. Most of the absorbed curcumin is rapidly 
metabolized into several metabolites (Figure 7) in the intestinal mucosa and the liver 
(Sharma et al., 2005). As a result, curcumin is usually formulated with bromelain to aid 
in absorption (Sharma et al., 2005). Bromelain is a class of sulfhydryl-containing 
proteolytic enzymes that is mainly extracted from a pineapple plant stem. Bromelain is 
mostly used as an oral supplement to help in digestion, and sometimes used topically as 
an anti-inflammatory agent (Baumann, 2008). 
Curcumin is a pleiotropic molecule and can interact with a number of different 
molecular targets, some of which are involved in inflammation. Curcumin helps in down- 
regulating enzymes such as cyclooxygenase-2 (COX-2), lipoxygenase, inducible nitric 
oxide synthase (iNOS), monocyte chemoattractant protein (MCP), migration inhibitory 
proteins, mitogen-activated protein kinases (MAPK), and Janus kinases (Reddy et al., 
2012; Sharma et al., 2005). These enzymes are either involved in the production of 
prostaglandins that mediate inflammation or control signals that elicit inflammatory 
reactions. This also helps in inhibiting the production of inflammation-mediating 
cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL) 1, 2, 6, 8, and 12. 
The anti-inflammatory activity of curcumin has also helped in alleviating a number of 
serious conditions. Conditions such as osteoarthritis, acute pancreatitis, and uveitis 
involve inflammatory responses (Reddy et al., 2012; Sharma et al., 2005). Treatment 
studies against these conditions using curcumin have shown great promise, and the 
results are a stepping-stone in finding other non-conventional treatments. 
Studies have shown that C. longa poses numerous medicinal potential. Among 
these are anthelminthic and anti-cancer activities. In a model using Indian earthworms, 
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Figure 7: Major Metabolites of Curcumin in Rodents and Humans. Reprinted from 
European Journal of Cancer, Vol 41, R.A. Sharma, A.J. Gescher, W.P. Steward, 
Curcumin: The story so far, 1955-1968, Copyright (2005), with permission from 
Elsevier. 
 
Pheretima posthuma, C. longa extracts were observed to paralyze and kill the 
earthworms. These observations led to the conclusion that C. longa extracts could 
potentially be used as an anthelminthic drug (Reddy et al., 2012). Also, rodents with 
mammary tumors induced by N-methyl-N-nitrosourea (MNU), an alkylating agent that 
interacts directly with DNA causing genomic mutations were tested with C. longa 
extracts before and after tumor induction in order to test the prophylactic and therapeutic 
potential of the plant (Reddy et al., 2012; Tsubura et al., 2011). 
The results were analyzed on the basis of latency period of the tumor, tumor 
incidence, tumor burden, tumor volume, tumor growth inhibition, histology and 
hematological parameters. The results showed a more effective response in the 
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prophylactic treatment compared to the therapeutic treatment, with topical doses having a 
greater effect than oral doses (Reddy et al., 2012). 
C. longa extracts have been observed to confer protection in the cardiovascular 
system. These extracts help in lowering cholesterol and triglyceride levels, which are 
associated with many cardiovascular disorders, and reduce the chances of peroxidation of 
low-density lipoprotein (LDL) (Reddy et al., 2012). Lipid peroxidation is one of the 
causes of oxidative stress in cells due to the production of free lipid radicals, damaging 
the cell membranes. Other cardiovascular effects of C. longa include inhibition of platelet 
aggregation, possibly through the inhibition of thromboxane synthesis (Reddy et al., 
2012). 
The aging process of cells is influenced by a number of factors, including lipid 
peroxidation that significantly damages cells, lipofuscin concentration and accumulation 
in neurons, and the activities of enzymes such as superoxide dismutase (SOD), 
glutathione peroxidase (GPx), and the Na+, K+ pump (Reddy et al., 2012). The influence 
of C. longa extracts on aging was tested on 6 and 24 month old rats. Long-term 
treatments with C. longa showed a significant drop in lipid peroxidation in the brain 
regions, as well as a drop in the lipofuscin contents. There was an observed increase in 
the activities of SOD, GPx, and the Na+, K+ pump in the brain regions as well (Reddy et 
al., 2012). These observations are consistent with that of a young growing mouse brain, 
indicating anti-aging prospects of C. longa extracts. 
The antimicrobial activity associated with C. longa is an important feature. 
 
Curcumin is the main component of C. longa that has shown antimicrobial capabilities. 
Previous studies have observed positive results against pathogens, including Escherichia 
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coli, Bacillus subtilis, Yersinia enterocolitica, Saccharomyces cerevisiae, Bacillus cereus, 
Aspergillus niger, Penicillium notatum, and S. aureus (Su-Hyun et al., 2014). Such 
successes have led to further tests on MRSA. 
Su-Hyun et al. performed an experiment to see whether curcumin could reverse 
MRSA’s resistance against antibiotics such as oxacillin. Su-Hyun et al. used both MRSA 
and MSSA strains and tested for the presence of mecA gene, and treated both strains with 
various concentrations of oxacillin alone, curcumin alone, and a combination of both. 
The MSSA strains were inhibited by all treatments. MRSA was overall unaffected by the 
oxacillin treatment (Su-Hyun et al., 2014). This was due to the production of PBP2a, 
which helped overcome the stress caused by oxacillin. The PBP2a levels were as 
expected. When treated with curcumin alone, the expression of PBP2a dropped 
significantly, and even better results were observed when both oxacillin and curcumin 
were used on MRSA (Figure 8) (Su-Hyun et al., 2014). This indicated a synergistic 
relationship between curcumin and oxacillin, which is similar to the one between extracts 
from A. wilkesiana and oxacillin (Su-Hyun et al., 2014). Curcumin lowers the expression 
of PBP2a in MRSA, which allows oxacillin to render the normal PBP non-functional, 
disrupting the bacterial cell wall synthesis, and killing the cell in the process. Results 
from such experiments may result in creating alternative treatments against MRSA, and 
may eventually provide relief against bacterial resistance to antibiotics. 
Over the years researchers have created a large number of antibiotics. Some of 
them are new classes of antibiotics, while others are derivatives of already existing ones. 
The need to create new and improved drugs is due to resistance associated with certain 
strains of bacteria, such as MRSA. However, overtime these strains develop resistance 
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Figure 8: Western blotting showing PBP2a expression on different MRSA strains. CON 
represents control sample, OX represents strains treated with oxacillin, and CCM 
represents strains treated with curcumin. GAPDH was used as the control protein (Su- 
Hyun et al., 2014). 
 
against newer medications, which leads further research in finding new drugs to counter- 
act MRSA’s resistance. This also creates the need for continuous funding into research 
for new drugs. Patients in critical conditions that are infected with MRSA have a much 
lower chance of survival due to physicians having trouble finding the right treatment 
course to administer. These are some of the problems that make the fight against MRSA 
even that much harder. 
The answer to these problems could lie with herbal extracts, such as curcumin. 
 
These extracts have shown to affect the resistivity of MRSA to common antibiotics. 
When the herbal extracts are augmented with antibiotics, the growth of bacteria is 
inhibited. This helps to avoid the need to constantly manufacture new antibiotics. The 
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millions of dollars spent in research to discover new antibiotics could be put to better use, 
such as funding research in cancer or HIV. Also, physicians can be confident that any 
treatment course administered will have a greater chance of success, which will give 
patients a much higher chance of survival. 
Although the use of herbal extracts as part of the current available treatments is 
still in its infancy, it has shown great promise. The world is filled with diverse group of 
plants, which would create a cheaper alternative to modern cures. 
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credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME], advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
 
 
6. Adaptations of single figures do not require NPG approval. However, the adaptation should 
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Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference 
citation), copyright (year of publication) 
 
Note: For adaptation from the British Journal of Cancer, the following credit line 
applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME] (reference citation), copyright (year of publication) 
 
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information.Translations of up 
to a 400 words do not require NPG approval. The translation should be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] (reference 
citation), copyright (year of publication). 
 
Note: For translation from the British Journal of Cancer, the following credit line 
applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[JOURNAL NAME] (reference citation), copyright (year of publication) 
 
We are certain that all parties will beneﬁt from this agreement and wish you the best in the 
use of this material. Thank you. 
Special Terms: 
v1.1 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777. 
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United States 
Attn: Mgayya Makullah 
Total 0.00 USD 
Terms and Conditions  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection 
with completing this licensing transaction, you agree that the following terms and conditions 
apply to this transaction (along with the Billing and Payment terms and conditions 
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your 
Rightslink account and that are available at any time at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to 
the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, ﬁgures) has 
appeared in our publication with credit or acknowledgement to another source, permission 
must also be sought from that source. If such permission is not obtained then that material 
may not be included in your publication/copies. Suitable acknowledgement to the source 
must be made, either as a footnote or in a reference list at the end of your publication, as 
follows: 
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of 
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE 
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The 
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier." 
4. Reproduction of this material is conﬁned to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However ﬁgures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions 
and/or any other alterations shall be made only with prior written authorization of Elsevier 
Ltd. (Please contact Elsevier at permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this instance, 
please be advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not speciﬁcally granted in the 
combination of (i) the license details provided by you and accepted in the course of this 
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
transaction, provided that you have disclosed complete and accurate details of your proposed 
use, no license is ﬁnally effective unless and until full payment is received from you (either 
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If 
full payment is not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted.  Further, in the event 
that you breach any of these terms and conditions or any of CCC's Billing and Payment 
terms and conditions, the license is automatically revoked and shall be void as if never 
granted. Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement 
and publisher reserves the right to take any and all action to protect its copyright in the 
materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and 
their respective ofﬁcers, directors, employees and agents, from and against any and all 
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claims arising out of your use of the licensed material other than as speciﬁcally authorized 
pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in awriting 
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment 
terms and conditions. These terms and conditions, together with CCC's Billing and Payment 
terms and conditions (which are incorporated herein), comprise the entire agreement 
between you and publisher (and CCC) concerning this licensing transaction. In the event of 
any conﬂict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions 
shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described 
in this License at their sole discretion, for any reason or no reason, with a full refund payable 
to you. Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier 
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage 
incurred by you as a result of a denial of your permission request, other than a refund of the 
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied 
permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to speciﬁc license types: 
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional translator 
must perform all translations and reproduce the content word for word preserving the 
integrity of the article. 
16. Posting licensed content on any Website: The following terms and conditions apply as 
follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright information line on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a 
scanned version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier 
homepage at http://www.elsevier.com . All content posted to the web site must maintain the 
copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following 
clauses are applicable: The web site must be password-protected and made available only to 
bona ﬁde students registered on a relevant course. This permission is granted for 1 year only. 
You may obtain a new license for future website posting. 
17. For journal authors: the following clauses are applicable in addition to the above: 
Preprints: 
A preprint is an author's own write-up of research results and analysis, it has not been peer- 
reviewed, nor has it had any other value added to it by a publisher (such as formatting, 
copyright, technical enhancement etc.). 
Authors can share their preprints anywhere at any time. Preprints should not be added to or 
enhanced in any way in order to appear more like, or to substitute for, the ﬁnal versions of 
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articles however authors can update their preprints on arXiv or RePEc with their Accepted 
Author Manuscript (see below). 
If accepted for publication, we encourage authors to link from the preprint to their formal 
publication via its DOI. Millions of researchers have access to the formal publications on 
ScienceDirect, and so links will help users to ﬁnd, access, cite and use the best available 
version. Please note that Cell Press, The Lancet and some society-owned have different 
preprint policies. Information on these policies is available on the journal homepage. 
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an 
article that has been accepted for publication and which typically includes author- 
incorporated changes suggested during submission, peer review and editor-author 
communications. 
Authors can share their accepted author manuscript: 
 
- immediately 
via their non-commercial person homepage or blog 
by updating a preprint in arXiv or RePEc with the accepted manuscript 
via their research institute or institutional repository for internal institutional 
uses or as part of an invitation-only research collaboration work-group 
directly by providing copies to their students or to research collaborators for 
their personal use 
for private scholarly sharing as part of an invitation-only work group on 
commercial sites with which Elsevier has an agreement 
- after the embargo period 
via non-commercial hosting platforms such as their institutional repository 
via commercial sites with which Elsevier has an agreement 
 
In all cases accepted manuscripts should: 
 
- link to the formal publication via its DOI 
- bear a CC-BY-NC-ND license - this is easy to do 
- if aggregated with other manuscripts, for example in a repository or other site, be 
shared in alignment with our hosting policy not be added to or enhanced in any way to 
appear more like, or to substitute for, the published journal article. 
 
Published journal article (JPA): A published journal article (PJA) is the deﬁnitive ﬁnal 
record of published research that appears or will appear in the journal and embodies all 
value-adding publishing activities including peer review co-ordination, copy-editing, 
formatting, (if relevant) pagination and online enrichment. 
Policies for sharing publishing journal articles differ for subscription and gold open access 
articles: 
Subscription Articles: If you are an author, please share a link to your article rather than the 
full-text. Millions of researchers have access to the formal publications on ScienceDirect, 
and so links will help your users to ﬁnd, access, cite, and use the best available version. 
Theses and dissertations which contain embedded PJAs as part of the formal submission can 
be posted publicly by the awarding institution with DOI links back to the formal 
publications on ScienceDirect. 
If you are afﬁliated with a library that subscribes to ScienceDirect you have additional 
private sharing rights for others' research accessed under that agreement. This includes use 
for classroom teaching and internal training at the institution (including use in course packs 
and courseware programs), and inclusion of the article for grant funding purposes. 
Gold Open Access Articles: May be shared according to the author-selected end-user 
license and should contain a CrossMark logo, the end user license, and a DOI link to the 
formal publication on ScienceDirect. 
Please refer to Elsevier's posting policy for further information. 
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18. For book authors the following clauses are applicable in addition to the above: 
Authors are permitted to place a brief summary of their work online only. You are not 
allowed to download and post the published electronic version of your chapter, nor may you 
scan the printed edition to create an electronic version. Posting to a repository: Authors are 
permitted to post a summary of their chapter only in their institution's repository. 
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be 
published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
the complete thesis and include permission for Proquest/UMI to supply single copies, on 
demand, of the complete thesis. Should your thesis be published commercially, please 
reapply for permission. Theses and dissertations which contain embedded PJAs as part of 
the formal submission can be posted publicly by the awarding institution with DOI links 
back to the formal publications on ScienceDirect. 
 
Elsevier Open Access Terms and Conditions 
You can publish open access with Elsevier in hundreds of open access journals or in nearly 
2000 established subscription journals that support open access publishing. Permitted third 
party re-use of these open access articles is deﬁned by the author's choice of Creative 
Commons user license. See our open access license policy for more information. 
Terms & Conditions applicable to all Open Access articles published with Elsevier: 
Any reuse of the article must not represent the author as endorsing the adaptation of the 
article nor should the article be modiﬁed in such a way as to damage the author's honour or 
reputation. If any changes have been made, such changes must be clearly indicated. 
The author(s) must be appropriately credited and we ask that you include the end user 
license and a DOI link to the formal publication on ScienceDirect. 
If any part of the material to be used (for example, ﬁgures) has appeared in our publication 
with credit or acknowledgement to another source it is the responsibility of the user to 
ensure their reuse complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new 
works from the Article, to alter and revise the Article and to make commercial use of the 
Article (including reuse and/or resale of the Article by commercial entities), provided the 
user gives appropriate credit (with a link to the formal publication through the relevant 
DOI), provides a link to the license, indicates if changes were made and the licensor is not 
represented as endorsing the use made of the work. The full details of the license are 
available at http://creativecommons.org/licenses/by/4.0. 
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, 
abstracts and new works from the Article, to alter and revise the Article, provided this is not 
done for commercial purposes, and that the user gives appropriate credit (with a link to the 
formal publication through the relevant DOI), provides a link to the license, indicates if 
changes were made and the licensor is not represented as endorsing the use made of the 
work. Further, any new works must be made available on the same conditions. The full 
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0. 
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, 
provided this is not done for commercial purposes and further does not permit distribution of 
the Article if it is changed or edited in any way, and provided the user gives appropriate 
credit (with a link to the formal publication through the relevant DOI), provides a link to the 
license, and that the licensor is not represented as endorsing the use made of the work. The 
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0. 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY 
NC ND license requires permission from Elsevier and will be subject to a fee. 
Commercial reuse includes: 
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- Associating advertising with the full text of the Article 
- Charging fees for document delivery or access 
- Article aggregation 
- Systematic distribution via e-mail lists or share buttons 
 
Posting or linking by commercial companies for use by customers of those companies. 
20. Other Conditions: 
v1.8 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777. 
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United States 
Attn: Mgayya Makullah 
Total 0.00 USD 
Terms and Conditions 
 
Wolters Kluwer Terms and Conditions 
 
1. Transfer of License: Wolters Kluwer hereby grants you a non-exclusive license to 
reproduce this material for this purpose, and for no other use, subject to the conditions 
herein. 
2. Credit Line: will be prominently placed and include: For books – the author(s), title of 
book, editor, copyright holder, year of publication; For journals – the author(s), title of 
article, title of journal, volume number, issue number, inclusive pages and website URL to 
the journal page. 
3. Warranties: The requestor warrants that the material shall not be used in any manner 
which may be considered derogatory to the title, content, or authors of the material, or to 
Wolters Kluwer. 
4. Indemnity: You hereby indemnify and hold harmless Wolters Kluwer and their respective 
officers, directors, employees and agents, from and against any and all claims, costs, 
proceeding or demands arising out of your unauthorized use of the Licensed Material. 
5. Geographical Scope: Permission granted is non-exclusive, and is valid throughout the 
world in the English language and the languages specified in your original request. 
6. Wolters Kluwer cannot supply the requestor with the original artwork, electronic files or a 
"clean copy." 
7. Permission is valid if the borrowed material is original to a Wolters Kluwer imprint 
(Lippincott-Raven Publishers, Williams & Wilkins, Lea & Febiger, Harwal, Rapid Science, 
Little Brown & Company, Harper & Row Medical, American Journal of Nursing Co, and 
Urban & Schwarzenberg - English Language, Raven Press, Paul Hoeber, Springhouse, 
Ovid). 
8. Termination of contract: If you opt not to use the material requested above please 
notify RightsLink or Wolters Kluwer within 90 days of the original invoice date. 
9. This permission does not apply to images that are credited to publications other than 
Wolters Kluwer books/journals or its Societies. For images credited to non-Wolters Kluwer 
books or journals, you will need to obtain permission from the source referenced in the 
figure or table legend or credit line before making any use of the image(s) or table(s). 
10. Modifications: With the exception of text size or color, no Wolters Kluwer material is 
permitted to be modified or adapted without publisher approval. 
11. Third party material: Adaptations are protected by copyright, so if you would like to 
reuse material that we have adapted from another source, you will need not only our 
permission, but the permission of the rights holder of the original material. Similarly, if you 
want to reuse an adaptation of original LWW content that appears in another publishers 
work, you will need our permission and that of the next publisher. The adaptation should  
be credited as follows: Adapted with permission from Wolters Kluwer: Book author, title, 
year of publication or Journal name, article author, title, reference citation, year of 
publication. Modifications are permitted on an occasional basis only and permission must  
be sought by Wolters Kluwer. 
12. Duration of the license: Permission is granted for a one-time use only within 12 months 
from the date of this invoice. Rights herein do not apply to future reproductions, editors, 
revisions, or other derivative works. Once the 12 - month term has expired, permission to 
renew must be submitted in writing. 
i. For content reused in another journal or book, in print or electronic format, the 
license is one-time use and lasts for the 1st edition of a book or for the life of the 
edition in case of journals. 
ii. If your Permission Request is for use on a website (which is not a journal or a book), 
internet, intranet, or any publicly accessible site, you agree to remove the material 
from such site after 12 months or else renew your permission request. 
13. Contingent on payment: While you may exercise the rights licensed immediately upon 
issuance of the license at the end of the licensing process for the transaction, provided that 
you have disclosed complete and accurate details of your proposed use, no license is finally 
effective unless and until full payment is received from you (either by publisher or by CCC) 
as provided in CCC's Billing and Payment terms and conditions. If full payment is not 
received on a timely basis, then any license preliminarily granted shall be deemed 
automatically revoked and shall be void as if never granted. Further, in the event that you 
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breach any of these terms and conditions or any of CCC's Billing and Payment terms and 
conditions, the license is automatically revoked and shall be void as if never granted. Use 
of materials as described in a revoked license, as well as any use of the materials beyond 
the scope of an unrevoked license, may constitute copyright infringement and publisher 
reserves the right to take any and all action to protect its copyright in the materials. 
14. Waived permission fee: If the permission fee for the requested use of our material has 
been waived in this instance, please be advised that your future requests for Wolters 
Kluwer materials may incur a fee. 
15. Service Description for Content Services: Subject to these terms of use, any terms set 
forth on the particular order, and payment of the applicable fee, you may make the 
following uses of the ordered materials: 
i. Content Rental: You may access and view a single electronic copy of the materials 
ordered for the time period designated at the time the order is placed. Access to the 
materials will be provided through a dedicated content viewer or other portal, and 
access will be discontinued upon expiration of the designated time period. An order 
for Content Rental does not include any rights to print, download, save, create 
additional copies, to distribute or to reuse in any way the full text or parts of the 
materials. 
ii. Content Purchase: You may access and download a single electronic copy of the 
materials ordered. Copies will be provided by email or by such other means as 
publisher may make available from time to time. An order for Content Purchase does 
not include any rights to create additional copies or to distribute copies of the 
materials. 
 
 
For Journals Only: 
 
1. Please note that articles in the ahead-of-print stage of publication can be cited and the 
content may be re-used by including the date of access and the unique DOI number. Any 
final changes in manuscripts will be made at the time of print publication and will be 
reflected in the final electronic version of the issue. Disclaimer: Articles appearing in the 
Published Ahead-of-Print section have been peer-reviewed and accepted for publication in 
the relevant journal and posted online before print publication. Articles appearing as  
publish ahead-of-print may contain statements, opinions, and information that have errors 
in facts, figures, or interpretation. Accordingly, Wolters Kluwer, the editors and authors and 
their respective employees are not responsible or liable for the use of any such inaccurate 
or misleading data, opinion or information contained in the articles in this section. 
2. Where a journal is being published by a learned society, the details of that society must be 
included in the credit line. 
i. For Open Access journals: The following statement needs to be added when 
reprinting the material in Open Access journals only: "promotional and commercial 
use of the material in print, digital or mobile device format is prohibited without the 
permission from the publisher Wolters Kluwer. Please contact 
healthpermissions@wolterskluwer.com for further information." 
ii. Exceptions: In case of reuse from Diseases of the Colon & Rectum, Plastic 
Reconstructive Surgery, The Green Journal, Critical Care Medicine, Pediatric 
Critical Care Medicine, the American Heart Association Publications and the 
American Academy of Neurology the following guideline applies: no drug/ trade 
name or logo can be included in the same page as the material re-used. 
3. Translations: If granted permissions to republish a full text article in another language, 
Wolters Kluwer should be sent a copy of the translated PDF. Please include disclaimer 
below on all translated copies: 
i. Wolters Kluwer and its Societies take no responsibility for the accuracy of 
the translation from the published English original and are not liable for any 
errors which may occur. 
4. Full Text Articles: Reuse of full text articles in English is prohibited. 
 
STM Signatories Only: 
 
1. Any permission granted for a particular edition will apply also to subsequent editions and 
for editions in other languages, provided such editions are for the work as a whole in situ 
and does not involve the separate exploitation of the permitted illustrations or excerpts. 
Please click here to view the STM guidelines. 
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Other Terms and Conditions: 
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Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
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This Agreement between Mgayya Makullah ("You") and Elsevier ("Elsevier") consists of 
your license details and the terms and conditions provided by Elsevier and Copyright 
Clearance Center. 
 
License Number 4004270332053 
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Licensed Content Publisher Elsevier 
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Number 
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United States 
Attn: Mgayya Makullah 
Total 0.00 USD 
Terms and Conditions  
INTRODUCTION 
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